SAFETY DATA SHEET
pBluescript II RI Predigested Vector, Part Number 212250

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name: pBluescript II RI Predigested Vector, Part Number 212250
Part No. (Kit): 212250
Part No.: pBluescript II RI
Predigested Vector
Kanamycin Resistance Gene Test Insert

1.2 Relevant identified uses of the substance or mixture and uses advised against

<table>
<thead>
<tr>
<th>Identified uses</th>
<th>0.055 ml (55 µl 20 ng/µl)</th>
<th>0.003 ml (3 µl 10 ng/µl)</th>
</tr>
</thead>
</table>
Analytical reagent.                        |                          |                          |
pBluescript II RI Predigested Vector       |                          |                          |
Kanamycin Resistance Gene Test Insert      |                          |                          |

1.3 Details of the supplier of the safety data sheet
Agilent Technologies Manufacturing GmbH & Co. KG
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000
e-mail address of person responsible for this SDS: pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation): CHEMTREC®: +(44)-870-8200418

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition: pBluescript II RI Mixture
Predigested Vector
Kanamycin Resistance Mixture
Gene Test Insert

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]
Not classified.

See Section 16 for the full text of the H statements declared above.
See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word: pBluescript II RI
Predigested Vector
Kanamycin Resistance
Gene Test Insert
No signal word.

Hazard statements: pBluescript II RI
Predigested Vector
Kanamycin Resistance
Gene Test Insert
No known significant effects or critical hazards.

Date of issue/Date of revision: 27/03/2017
SECTION 2: Hazards identification

Precautionary statements

**Prevention**
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

**Response**
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

**Storage**
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

**Disposal**
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

Supplemental label elements
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

Special packaging requirements

Tactile warning of danger
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: Not applicable.

2.3 Other hazards

Other hazards which do not result in classification
- pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: None known.

SECTION 3: Composition/information on ingredients

3.1 Substances
- pBluescript II RI Predigested Vector: Mixture
- Kanamycin Resistance Gene Test Insert: Mixture

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard
[2] Substance with a workplace exposure limit
[5] Substance of equivalent concern

Occupational exposure limits, if available, are listed in Section 8.
## SECTION 4: First aid measures

### 4.1 Description of first aid measures

<table>
<thead>
<tr>
<th>Eye contact</th>
<th>pBluescript II RIGenentigested Vector</th>
<th>Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.</td>
</tr>
<tr>
<td>Inhalation</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td>Skin contact</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td>Ingestion</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.</td>
</tr>
<tr>
<td>Protection of first-aiders</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>No action shall be taken involving any personal risk or without suitable training.</td>
</tr>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>No action shall be taken involving any personal risk or without suitable training.</td>
</tr>
</tbody>
</table>

### 4.2 Most important symptoms and effects, both acute and delayed

#### Potential acute health effects

<table>
<thead>
<tr>
<th>Eye contact</th>
<th>pBluescript II RIGenentigested Vector</th>
<th>No known significant effects or critical hazards.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td>Inhalation</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td>Skin contact</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td>Ingestion</td>
<td>pBluescript II RIGenentigested Vector</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>No known significant effects or critical hazards.</td>
</tr>
</tbody>
</table>

#### Over-exposure signs/symptoms

<table>
<thead>
<tr>
<th>Eye contact</th>
<th>pBluescript II RIGenentigested Vector</th>
<th>No specific data.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

---

**Date of issue/Date of revision**: 27/03/2017
SECTION 4: First aid measures

Inhalation: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. No specific data.

Skin contact: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. No specific data.

Ingestion: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

Kanamycin Resistance Gene Test Insert. Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.


SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. Use an extinguishing agent suitable for the surrounding fire.


5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. In a fire or if heated, a pressure increase will occur and the container may burst.


5.3 Advice for firefighters

Special precautions for fire-fighters: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters: pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert. Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

Date of issue/Date of revision: 27/03/2017
**SECTION 5: Firefighting measures**

face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

**SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

| For non-emergency personnel | pBluescript II RI Predigested Vector | No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment. |
| Kanamycin Resistance Gene Test Insert | No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment. |

| For emergency responders | pBluescript II RI Predigested Vector | If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". |
| Kanamycin Resistance Gene Test Insert | If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". |

### 6.2 Environmental precautions

| pBluescript II RI Predigested Vector | Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). |
| Kanamycin Resistance Gene Test Insert | Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). |

### 6.3 Methods and material for containment and cleaning up

| pBluescript II RI Predigested Vector | Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor. |
| Kanamycin Resistance Gene Test Insert | Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor. |

### 6.4 Reference to other sections

- See Section 1 for emergency contact information.
- See Section 8 for information on appropriate personal protective equipment.
- See Section 13 for additional waste treatment information.

**SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

| pBluescript II RI Predigested Vector | Put on appropriate personal protective equipment (see Section 8). |
| Kanamycin Resistance Gene Test Insert | Put on appropriate personal protective equipment (see Section 8). |

**Date of issue/Date of revision**: 27/03/2017
SECTION 7: Handling and storage

**Advice on general occupational hygiene**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Storage Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>pBluescript II RI Predigested Vector</td>
<td>Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.</td>
</tr>
<tr>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.</td>
</tr>
</tbody>
</table>

**7.2 Conditions for safe storage, including any incompatibilities**

<table>
<thead>
<tr>
<th>Substance</th>
<th>Storage Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>pBluescript II RI Predigested Vector</td>
<td>Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.</td>
</tr>
<tr>
<td>Kanamycin Resistance Gene Test Insert</td>
<td>Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.</td>
</tr>
</tbody>
</table>

**7.3 Specific end use(s)**

| Recommendations |
|------------------|-------------------------------------------------|
| pBluescript II RI Predigested Vector | Industrial applications, Professional applications. |
| Kanamycin Resistance Gene Test Insert | Industrial applications, Professional applications. |

**Industrial sector specific solutions**

| Recommendations |
|------------------|-------------------------------------------------|
| pBluescript II RI Predigested Vector | Not applicable. |
| Kanamycin Resistance Gene Test Insert | Not applicable. |

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

**Occupational exposure limits**

No exposure limit value known.

**Recommended monitoring procedures**

If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

**DNELs/DMELs**

**Date of issue/Date of revision**

<table>
<thead>
<tr>
<th>Date of issue/Date of revision</th>
</tr>
</thead>
<tbody>
<tr>
<td>27/03/2017</td>
</tr>
</tbody>
</table>
SECTION 8: Exposure controls/personal protection

No DNELs/DMELs available.

PNECs
No PNECs available

8.2 Exposure controls

Appropriate engineering controls

Individual protection measures

Hand protection

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. According to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Respiratory protection

: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state

: pBluescript II RI Predigested Vector Liquid.
   Kanamycin Resistance Gene Test Insert Liquid.

Colour

: pBluescript II RI Predigested Vector
   Kanamycin Resistance Gene Test Insert Not available.

Odour

: pBluescript II RI Predigested Vector
   Kanamycin Resistance Gene Test Insert Not available.

Odour threshold

: pBluescript II RI Predigested Vector
   Kanamycin Resistance Gene Test Insert Not available.

Date of issue/Date of revision : 27/03/2017
**SECTION 9: Physical and chemical properties**

<table>
<thead>
<tr>
<th>Property</th>
<th>pBluescript II RI Predigested Vector</th>
<th>Kanamycin Resistance Gene Test Insert</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>7.5</td>
<td>7.5</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>0°C</td>
<td>0°C</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>100°C</td>
<td>100°C</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable.</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Upper/lower flammability or explosive limits</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Vapour density</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Relative density</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Easily soluble in the following materials: cold water and hot water.</td>
<td>Easily soluble in the following materials: cold water and hot water.</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Not available.</td>
<td>Not available.</td>
</tr>
</tbody>
</table>

**Date of issue/Date of revision**: 27/03/2017
SECTION 9: Physical and chemical properties

Explosive properties: Not available.

Oxidising properties: Not available.

SECTION 10: Stability and reactivity

10.1 Reactivity: No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability: The product is stable.

10.3 Possibility of hazardous reactions: Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid: No specific data.

10.5 Incompatible materials: May react or be incompatible with oxidising materials.

10.6 Hazardous decomposition products: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity: Not available.

Acute toxicity estimates: Not available.

Irritation/Corrosion: Not available.

Conclusion/Summary: Not available.

Specific target organ toxicity (single exposure): Not available.

Date of issue/Date of revision: 27/03/2017
SECTION 11: Toxicological information

Specific target organ toxicity (repeated exposure)
Not available.

Aspiration hazard
Not available.

Information on likely routes of exposure

- **Inhalation**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.
  - Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.

Potential acute health effects

- **Inhalation**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.
  - Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.

- **Ingestion**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.
  - Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.

- **Skin contact**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.
  - Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.

- **Eye contact**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.
  - Kanamycin Resistance Gene Test Insert: No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

- **Inhalation**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No specific data.

- **Ingestion**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No specific data.

- **Skin contact**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No specific data.

- **Eye contact**
  - pBluescript II RI Predigested Vector Kanamycin Resistance Gene Test Insert: No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure**

- **Potential immediate effects**
  - Not available.

- **Potential delayed effects**
  - Not available.

**Long term exposure**

- **Potential immediate effects**
  - Not available.

- **Potential delayed effects**
  - Not available.

Potential chronic health effects
SECTION 11: Toxicological information

General

- pBluescript II RI Predigested Vector
  - Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

- Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

Carcinogenicity

- pBluescript II RI Predigested Vector
  - Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

Mutagenicity

- pBluescript II RI Predigested Vector
  - Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

Teratogenicity

- pBluescript II RI Predigested Vector
  - Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

Developmental effects

- pBluescript II RI Predigested Vector
  - Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

Fertility effects

- pBluescript II RI Predigested Vector
  - Kanamycin Resistance Gene Test Insert
  - No known significant effects or critical hazards.

SECTION 12: Ecological information

12.1 Toxicity

Conclusion/Summary

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (K_{OC})

- Not available.

Mobility

- Not available.

12.5 Results of PBT and vPvB assessment

PBT

- Not applicable.

vPvB

- Not applicable.

12.6 Other adverse effects

- No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal

The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Date of issue/Date of revision

: 27/03/2017
SECTION 13: Disposal considerations

**Hazardous waste** : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

**Packaging**

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

**Regulatory information**

**ADR/RID / IMDG / IATA** : Not regulated.

**14.6 Special precautions for user** : Transport within user’s premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**14.7 Transport in bulk according to Annex II of Marpol and the IBC Code** : Not available.

SECTION 15: Regulatory information

**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

**EU Regulation (EC) No. 1907/2006 (REACH)**

**Annex XIV - List of substances subject to authorisation**

**Annex XIV**

None of the components are listed.

**Substances of very high concern**

None of the components are listed.

**Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles**

None of the components are listed.

**Ozone depleting substances (1005/2009/EU)**

Not listed.

**Prior Informed Consent (PIC) (649/2012/EU)**

Not listed.

**Seveso Directive**

This product is not controlled under the Seveso Directive.

**International regulations**

**Chemical Weapon Convention List Schedules I, II & III Chemicals**

Not listed.

**Montreal Protocol (Annexes A, B, C, E)**

Not listed.

**Stockholm Convention on Persistent Organic Pollutants**

Not listed.

Date of issue/Date of revision : 27/03/2017
SECTION 15: Regulatory information

Rotterdam Convention on Prior Informed Consent (PIC)
Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals
Not listed.

International lists
National inventory
Australia: All components are listed or exempted.
Canada: All components are listed or exempted.
China: All components are listed or exempted.
Japan: Japan inventory (ENCS): All components are listed or exempted.
         Japan inventory (ISHL): All components are listed or exempted.
Malaysia: Not determined.
New Zealand: All components are listed or exempted.
Philippines: All components are listed or exempted.
Republic of Korea: All components are listed or exempted.
Taiwan: All components are listed or exempted.
Turkey: Not determined.
United States: All components are listed or exempted.

15.2 Chemical safety assessment
This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms
ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

<table>
<thead>
<tr>
<th>Classification</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not classified.</td>
<td></td>
</tr>
</tbody>
</table>

Full text of abbreviated H statements
Not applicable.

Full text of classifications [CLP/GHS]
Not applicable.

Date of issue/Date of revision: 27/03/2017
Date of previous issue: No previous validation.
Version: 1

Notice to reader
Disclaimer: The information contained in this document is based on Agilent’s state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.